Lanham Act: brand owners’ current weapon of choice
Since the outbreak of COVID-19, US federal courts have seen an uptick in Lanham Act cases. Unlike a typical Lanham Act case dealing solely with some form of trademark infringement or dilution, these cases have largely attacked third-party price-gouging of key medical supplies needed to combat the disease.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
12 May 2020 A trademark infringement complaint filed by 3M is “short on ultimate facts and long on inflammatory, derogatory, and conclusory assertions”, according to the company accused of price-gouging in the suit.
5 May 2020 3M has filed four more trademark lawsuits against companies accused of reselling N95 masks at inflated prices amid the COVID-19 pandemic, while also securing a preliminary injunction in another suit.
21 June 2017 The perceived problem with 35 USC section 101 is a “fundamental question of national innovation policy”, claimed Kevin Rhodes, vice president and chief IP counsel at multinational conglomerate 3M.